- Navigating Your Midlife Crisis: Embracing New Possibilities
- City Raccoons Showing Signs of Domestication
- Mapping the Exposome: Science Broadens Focus to Environmental Disease Triggers
- One Week Less on Social Media Linked to Better Mental Health
- Your Brain Changes in Stages as You Age, Study Finds
- Some Suicide Victims Show No Typical Warning Signs, Study Finds
- ByHeart Formula Faces Lawsuits After Babies Sickened With Botulism
- Switch to Vegan Diet Could Cut Your Greenhouse Gas Emissions in Half
- Regular Bedtime Does Wonders for Blood Pressure
- Dining Alone Could Mean Worse Nutrition for Seniors
Movantik Approved for Constipation From Opioids

Movantik (naloxegol) has been approved by the U.S. Food and Drug Administration to treat opioid-induced constipation, the agency said Tuesday.
Opioids are powerful painkillers that commonly cause constipation. Movantik’s safety and effectiveness to treat the problem were evaluated in two clinical studies involving 1,352 people who had taken opioids for at least four weeks for non-cancer related pain.
The most common side effects of Movantik were abdominal pain, diarrhea, headache and excessive gas, the FDA said in a news release.
Manufacturer AstraZeneca will be required to do an additional study to further evaluate the drug’s cardiovascular safety, the agency added.
AstraZeneca is based in Wilmington, Del.
More information
Visit the FDA to learn more.
Source: HealthDay
Copyright © 2025 HealthDay. All rights reserved.










